- Home
- RQI vs MNKD Comparison
RQI vs MNKD Comparison
Compare RQI & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RQI
- MNKD
- Stock Information
- Founded
- RQI 2002
- MNKD 1991
- Country
- RQI United States
- MNKD United States
- Employees
- RQI N/A
- MNKD N/A
- Industry
- RQI Trusts Except Educational Religious and Charitable
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- RQI Finance
- MNKD Health Care
- Exchange
- RQI Nasdaq
- MNKD Nasdaq
- Market Cap
- RQI 1.7B
- MNKD 1.4B
- IPO Year
- RQI N/A
- MNKD 2004
- Fundamental
- Price
- RQI $12.37
- MNKD $4.56
- Analyst Decision
- RQI
- MNKD Buy
- Analyst Count
- RQI 0
- MNKD 6
- Target Price
- RQI N/A
- MNKD $8.92
- AVG Volume (30 Days)
- RQI 432.6K
- MNKD 1.5M
- Earning Date
- RQI 01-01-0001
- MNKD 05-08-2025
- Dividend Yield
- RQI 8.20%
- MNKD N/A
- EPS Growth
- RQI N/A
- MNKD 215.86
- EPS
- RQI N/A
- MNKD 0.10
- Revenue
- RQI N/A
- MNKD $297,595,000.00
- Revenue This Year
- RQI N/A
- MNKD $14.23
- Revenue Next Year
- RQI N/A
- MNKD $14.56
- P/E Ratio
- RQI N/A
- MNKD $46.04
- Revenue Growth
- RQI N/A
- MNKD 32.50
- 52 Week Low
- RQI $9.17
- MNKD $4.17
- 52 Week High
- RQI $12.64
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- RQI 57.16
- MNKD 38.80
- Support Level
- RQI $12.21
- MNKD $4.42
- Resistance Level
- RQI $12.55
- MNKD $5.05
- Average True Range (ATR)
- RQI 0.20
- MNKD 0.18
- MACD
- RQI 0.07
- MNKD 0.00
- Stochastic Oscillator
- RQI 82.00
- MNKD 20.59
About RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the Fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.